Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2024-09-13 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, purchaser information, compensation paid, and regulatory references to National Instrument 45-106. This form is a regulatory filing used to report exempt distributions of securities, typically filed with Canadian securities regulators. It is not a financial report like an annual or quarterly report, nor is it an earnings release or management discussion. It is a specific regulatory filing reporting exempt distribution details, which fits best under the category 'Regulatory Filings (RNS)'. The document length is substantial and contains detailed data, confirming it is the report itself, not just an announcement of a report publication.
2024-09-13 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of a new board advisor and a new digital marketing services agreement. It contains no financial statements, no detailed financial performance data, no voting results, no regulatory certifications, and no mention of report attachments or filings. The content focuses on management/board changes and corporate updates. Therefore, it fits best under Board/Management Information (MANG). The document length is short (3700 characters), and it is not an announcement of a report publication or regulatory filing. Hence, the classification is MANG with high confidence.
2024-09-05 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a private placement financing and plans for additional financing by Sona Nanotech Inc. It details the amount raised, share issuance, finder fees, and intended use of proceeds. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The content focuses on fundraising activities and capital structure changes. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about financing, not just an announcement of a report publication or a regulatory filing. Hence, the classification is CAP with high confidence.
2024-09-05 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing Sona Nanotech's plan to raise capital through a private placement financing. It details the amount to be raised, the number of shares, pricing, use of proceeds, finder compensation, and regulatory approval requirements. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The content focuses solely on the financing activity and capital raising. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 5507 characters, which is sufficient to contain substantive information about the financing rather than just a brief announcement or a report publication notice.
2024-07-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-06-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing preclinical study results of a cancer therapy by Sona Nanotech Inc. It discusses scientific findings, experimental data, and future plans for clinical trials. There is no indication that this is a financial report, regulatory filing, or any formal corporate filing. It is a news announcement about scientific progress and company developments, not a financial or governance document. Therefore, it does not fit into categories like Annual Report, Earnings Release, Regulatory Filings, or others related to financial or corporate governance disclosures. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-06-26 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.